Form 4: BioMarin Executive Acquires Shares Through RSU Vesting

EVP and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

Summary

• On February 25, 2025, George Eric Davis, EVP and Chief Legal Officer of BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs).
• The RSUs were earned based on performance metrics related to total shareholder return, development goals, and core operating margin over the period of 2022-2024.
• A total of 11,040 RSUs were earned based on relative total shareholder return.
• 9,660 RSUs were earned based on the number and nature of development goals achieved.
• 9,367 RSUs were earned based on core operating margin.
• Although earned, the RSUs vest on March 15, 2025, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of RSUs suggests that performance targets were met, which is a positive indicator. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The vesting of RSUs indicates that performance goals related to shareholder return, development, and operating margin were met, which is a positive sign for the company's performance.

Future Outlook

The RSUs will vest on March 15, 2025, subject to the reporting person's continued service through that date.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and equity awards, common in the pharmaceutical industry to incentivize and retain key personnel. The performance-based nature of the RSU grants aligns executive interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize RSUs and stock options to incentivize executives based on performance metrics such as shareholder return and achievement of development milestones.
• The specific metrics used (shareholder return, development goals, operating margin) are common indicators of company performance in the biotech sector.

Stakeholder Impact

• Shareholders may view the vesting of RSUs as a positive sign, indicating that performance goals were achieved.
• Employees may be motivated by the fact that executives are incentivized to meet performance targets.

Next Steps

• The RSUs will vest on March 15, 2025, assuming continued service of the reporting person.

Key Dates